Anti-αvβ3 Integrin Recombinant Antibody (TAB-705) (CAT#: TAB-705)

Bayat, Behnaz, et al. "Current anti-HPA-1a standard antibodies react with the β3 integrin subunit but not with αIIbβ3 and αvβ3 complexes." Thrombosis and haemostasis 119.11 (2019): 1807-1815. https://doi.org/10.1055/s-0039-1696716

This research investigated the reactivity patterns of anti-HPA-1a standard antibodies used for diagnosing and predicting fetal/neonatal alloimmune thrombocytopenia (FNAIT) severity. Using flow cytometry, adsorption experiments, and functional assays, the study demonstrated that current standard materials (NIBSC 03/152) and human monoclonal antibodies (26.4 and 813) primarily recognize epitopes on the β3 integrin subunit independently, rather than αIIbβ3 or αvβ3 complexes. Significantly, these antibodies lack reactivity with αvβ3 complexes that were predominantly found in severe FNAIT cases with intracranial hemorrhage (ICH). All tested standard antibodies failed to inhibit endothelial tube formation, unlike anti-HPA-1a antibodies from ICH-positive cases.
Creative Biolabs supplied the therapeutic human monoclonal antibody etaracizumab (humanized murine moab LM609) which targets the αvβ3 complex for this research. This antibody served as a critical control, demonstrating strong reactivity with αvβ3 and completely blocking endothelial tube formation in functional assays, unlike the anti-HPA-1a standard antibodies. The inclusion of etaracizumab helped establish the distinct binding profiles of different antibody subtypes and highlighted the absence of anti-αvβ3 activity in current standard materials, revealing a significant limitation in their ability to predict severe FNAIT cases with intracranial hemorrhage risk.